<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19105704</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-8328</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of anticancer therapy</Title>
          <ISOAbbreviation>Expert Rev Anticancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Gefitinib for the treatment of non-small-cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>17</StartPage>
          <EndPage>35</EndPage>
          <MedlinePgn>17-35</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1586/14737140.9.1.17</ELocationID>
        <Abstract>
          <AbstractText>Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of objective tumor regressions with gefitinib in NSCLC patients has resulted in intense, worldwide clinical and basic research directed toward finding the optimal use of gefitinib in NSCLC. A recent large international Phase III study (IRESSA NSCLC Trial Evaluating Response and Survival Against Taxotere [INTEREST]) comparing gefitinib and docetaxel in unselected pretreated patients showed equivalent survival with better tolerability and quality of life. In addition, a Phase III study (WJTOG0203) evaluating gefitinib as sequential therapy after platinum-doublet chemotherapy showed the improved progression-free survival time. Furthermore, a large-scale randomized study (IRESSA Pan-Asia study [IPASS]) comparing gefitinib monotherapy with carboplatin/paclitaxel for previously untreated patients with adenocarcinoma who were never- or light-smokers showed an improved progression-free survival time in the gefitinib arm. A smaller Phase III study of pretreated Japanese patients (V-15-32) also demonstrated no difference in overall survival compared with docetaxel, with a statistically greater overall response rate. Somatic mutations in the EGFR gene, the target of gefitinib, were associated with dramatic and durable regressions in patients with NSCLC. Currently, investigators are trying to determine the optimal approach to select patients for treatment with gefitinib. This article aims to briefly summarize the profile of gefitinib, EGFR mutations, landmark trials with gefitinib and, also, ongoing trials that may herald an era of individualized therapy in at least some NSCLC patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hida</LastName>
            <ForeName>Toyoaki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center Hospital, Kanokoden, Chikusa-ku, Nagoya, Japan. 107974@aichi-cc.jp</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogawa</LastName>
            <ForeName>Shizu</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Jang Chul</ForeName>
            <Initials>JC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Ji Young</ForeName>
            <Initials>JY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Junichi</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horio</LastName>
            <ForeName>Yoshitsugu</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Kimihide</ForeName>
            <Initials>K</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Rev Anticancer Ther</MedlineTA>
        <NlmUniqueID>101123358</NlmUniqueID>
        <ISSNLinking>1473-7140</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>114</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>12</Month>
          <Day>25</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19105704</ArticleId>
        <ArticleId IdType="doi">10.1586/14737140.9.1.17</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
